TScan reports complete chimerism in 11 patients

• TScan reported initial Phase 1 data showing 11 out of 14 blood cancer patients reached complete donor chimerism.
• Following the announcement, the company's shares traded down at $0.89.
• The company expects to enroll its first Phase 3 trial patient within the current month.

TScan Therapeutics (NASDAQ:TCRX) reported initial clinical trial data showing 11 out of 14 blood cancer patients achieved complete donor chimerism.

The ongoing study evaluated the safety and efficacy of the company's TSC-101 treatment in patients undergoing cell transplantation.

Out of 19 total enrolled patients, 17 had successful manufacturing and 14 proceeded to receive their initial infusion.

The clinical data indicated that the candidate remained generally well-tolerated with safety results matching previous clinical experience.

TScan stated it remains on track to enroll the first patient in its pivotal Phase 3 study this month.

The company scheduled a virtual key opinion leader event on June 22, 2026, to discuss these clinical developments.